Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials

Andrei ShustovDepartment of Hematology, University of Washington Medical Center, Seattle, WA, USA; Correspondence[email protected]

Bertrand CoiffierDepartment of Hematology, Hospices Civils de Lyon, Lyon, France;

Steven HorwitzDepartment of Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA;

Lubomir SokolDepartment of Hematology, Moffitt Cancer Center, Tampa, FL, USA;

Barbara ProDepartment of Hematology/Oncology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA;

Julie WolfsonVeristat, LLC, Southborough, MA, USA;

Barbara BalserVeristat, LLC, Southborough, MA, USA;

Robin EischDepartment of Investigational Therapeutics, National Cancer Institute, Bethesda, MD, USA;

Leslie PopplewellDepartment of Hematology/Oncology, City of Hope Medical Center-Oncology, Duarte, CA, USA;

H. Miles PrinceDepartment of Hematology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia;

Steven L. AllenDepartment of Hematology, Hofstra North Shore-LIJ School of Medicine and Monter Cancer Center, Lake Success, NY, USA;

Richard PiekarzDepartment of Investigational Therapeutics, National Cancer Institute, Bethesda, MD, USA;

Susan BatesDepartment of Hematology/Oncology, Columbia University Medical Center, New York, NY, USA

Your download is now in progress and you may close this window